194 related articles for article (PubMed ID: 31361026)
21. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
22. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
24. Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism.
Takahashi R; Sato Y; Kimishima M; Shiohara T; Ohyama M
Int J Clin Oncol; 2020 Oct; 25(10):1861-1869. PubMed ID: 32656742
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
Koppolu V; Rekha Vasigala VK
J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of programmed cell death-1 and human leucocyte antigen-DR on circulatory regulatory T cells in out-of-hospital cardiac arrest patients in the early period after return of spontaneous circulation.
Qi Z; Liu Q; Zhang Q; Liu B; Li C
Resuscitation; 2018 Sep; 130():13-20. PubMed ID: 29940295
[TBL] [Abstract][Full Text] [Related]
27. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Daud AI; Loo K; Pauli ML; Sanchez-Rodriguez R; Sandoval PM; Taravati K; Tsai K; Nosrati A; Nardo L; Alvarado MD; Algazi AP; Pampaloni MH; Lobach IV; Hwang J; Pierce RH; Gratz IK; Krummel MF; Rosenblum MD
J Clin Invest; 2016 Sep; 126(9):3447-52. PubMed ID: 27525433
[TBL] [Abstract][Full Text] [Related]
28. Dynamic changes in circulating PD-1
Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
[TBL] [Abstract][Full Text] [Related]
29. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
[TBL] [Abstract][Full Text] [Related]
30. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
Yamaguchi K; Mishima K; Ohmura H; Hanamura F; Ito M; Nakano M; Tsuchihashi K; Ota SI; Wada N; Uchi H; Ariyama H; Kusaba H; Niiro H; Akashi K; Baba E
Cancer Sci; 2018 Oct; 109(10):3032-3042. PubMed ID: 30066977
[TBL] [Abstract][Full Text] [Related]
31. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
32. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
33. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
[TBL] [Abstract][Full Text] [Related]
34. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
[TBL] [Abstract][Full Text] [Related]
35. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
36. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
37. Imbalance between Subpopulations of Regulatory T Cells in Patients with Acute Exacerbation of COPD.
Yang X; Huo B; Zhong X; Su W; Liu W; Li Y; He Z; Bai J
COPD; 2017 Dec; 14(6):618-625. PubMed ID: 29166179
[TBL] [Abstract][Full Text] [Related]
38. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
40. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.
Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R
Front Immunol; 2021; 12():733961. PubMed ID: 34675925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]